St. Luke's Boise Medical Center in Boise, Idaho, is a 437-bed hospital founded in 1902 by James Bowen Funsten, bishop of the Episcopal Diocese of Idaho. The hospital is part of St. Luke's, a regional healthcare system with six hospitals and more than 200 clinics staffed by roughly 14,000 employees.

There are 437 beds in St. Luke's Regional Medical Center.

During the past decade, St. Luke's Regional Medical Center conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 7 clinical trials were completed, i.e. on average, 35% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 6 clinical trials were completed. i.e. 54.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "St. Luke's Regional Medical Center" #1 sponsor was "Jaeb Center for Health Research" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Abbott Medical Devices" with 2 trials sponsored, "Alliance for Clinical Trials in Oncology" with 2 trials sponsored and "Wake Forest University Health Sciences" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "St. Luke's Regional Medical Center" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 4 trials as a collaborator, "Beat NB Cancer Foundation" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator and "Team Parker for Life" with 2 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "St. Luke's Regional Medical Center" are "Amblyopia" (2 trials), "Breast Cancer" (2 trials), "Heart Failure With Preserved Ejection Fraction" (2 trials), "Neuroblastoma" (2 trials) and "Paroxysmal Atrial Fibrillation" (2 trials). Many other conditions were trialed in "St. Luke's Regional Medical Center" in a lesser frequency.

Most popular intervention types in "St. Luke's Regional Medical Center" are "Drug" (13 trials), "Device" (6 trials), "Other" (6 trials), "Biological" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "whole breast irradiation" (2 trials), "AZLI" (1 trials), "Atropine" (1 trials) and "CM-4620 Injectable Emulsion or CM-4620-IE" (1 trials). Other intervention names were less common.

The vast majority of trials in "St. Luke's Regional Medical Center" are 23 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "St. Luke's Regional Medical Center". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in St. Luke's Regional Medical Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in St. Luke's Regional Medical Center, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".

St. Luke's Regional Medical Center has several departments that took part in Clinical trials: "St. Luke's Children's Hospital" - 2 trials, "St. Luke's Children's Endocrinology" - 2 trials